Johnson & Johnson's CEO Alex Gorsky will make responsible drug pricing a priority in the coming year after meeting with President Donald Trump, according to a Yahoo Finance report.
Here are five key notes:
1. After the meeting, Mr. Gorsky said he would like to see changes to the U.S. tax code and healthcare policy.
2. Johnson & Johnson had a turbulent start to the year, with 2016 fourth quarter sales falling short of expectations.
3. Johnson & Johnson was the first major healthcare company to report sales after Mr. Trump criticized the high prices of medications. The company reported it would limit annual product price increases to single digits in percentage terms.
4. The company is planning to release a pharmaceutical transparency report and expand disclosures on U.S. pricing, research and development expenses.
5. Mr. Gorsky said the company will also disclose compassionate care programs.